Literature DB >> 24875752

Low- and high-grade bladder cancer appraisal via serum-based proteomics approach.

Navneeta Bansal1, Ashish Gupta2, Satya Narain Sankhwar3, Abbas Ali Mahdi4.   

Abstract

OBJECTIVE: To address the shortcomings of urine cytology and cystoscopy for screening and grading of urinary bladder cancer (BC) we applied a serum-based proteomics approach as a surrogate tactic for rapid BC probing.
METHODS: This study was performed on 90 sera samples comprising of low-grade (LG, n=33) and high-grade (HG, n=32) BC, and healthy controls (HC, n=25). Two-dimensional gel electrophoresis (2DE) tactic was executed to describe serum proteome. MALDI-TOF-MS (MS) was used to identify the characteristics of aberrantly expressed proteins in 2DE and validated using Western blot (WB) and ELISA approach. Receiver operating characteristics (ROC) curve analysis was also performed to determine the clinical usefulness of these proteins to discriminate among LG, HG and HC cohorts.
RESULTS: This comprehensive approach of 2DE, MS, WB and ELISA reveals five differentially expressed proteins. Among them two biomarkers (S100A8 and S100A9) were able to accurately (ROC, 0.946) distinguish 81% of BC (LG+HG) cases compared to HC with highest sensitivity and specificity. With a comparable tactic, two biomarkers (S100A8 and S100A4) were able to precisely (ROC, 0.941) discriminate 92% of LG cases from HG with utmost sensitivity and specificity.
CONCLUSIONS: Serum proteomics probing appears to be an encouraging and least-invasive tactic for screening and grading of BC.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Serum proteomics; Two-dimensional gel electrophoresis; Urinary bladder cancer

Mesh:

Year:  2014        PMID: 24875752     DOI: 10.1016/j.cca.2014.05.012

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  16 in total

Review 1.  Recent advances in the metabolomic study of bladder cancer.

Authors:  Chandra Sekhar Amara; Venkatrao Vantaku; Yair Lotan; Nagireddy Putluri
Journal:  Expert Rev Proteomics       Date:  2019-02-26       Impact factor: 3.940

2.  Canine urothelial carcinoma: genomically aberrant and comparatively relevant.

Authors:  S G Shapiro; S Raghunath; C Williams; A A Motsinger-Reif; J M Cullen; T Liu; D Albertson; M Ruvolo; A Bergstrom Lucas; J Jin; D W Knapp; J D Schiffman; M Breen
Journal:  Chromosome Res       Date:  2015-03-18       Impact factor: 5.239

3.  Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival.

Authors:  Venkatrao Vantaku; Sri Ramya Donepudi; Danthasinghe Waduge Badrajee Piyarathna; Chandra Sekhar Amara; Chandrashekar R Ambati; Wei Tang; Vasanta Putluri; Darshan S Chandrashekar; Sooryanarayana Varambally; Martha K Terris; Kimberly Davies; Stefan Ambs; Roni Bollag; Andrea B Apolo; Arun Sreekumar; Nagireddy Putluri
Journal:  Cancer       Date:  2019-01-02       Impact factor: 6.860

4.  Characterization and noninvasive diagnosis of bladder cancer with serum surface enhanced Raman spectroscopy and genetic algorithms.

Authors:  Shaoxin Li; Linfang Li; Qiuyao Zeng; Yanjiao Zhang; Zhouyi Guo; Zhiming Liu; Mei Jin; Chengkang Su; Lin Lin; Junfa Xu; Songhao Liu
Journal:  Sci Rep       Date:  2015-05-07       Impact factor: 4.379

Review 5.  Proteomics in India: the clinical aspect.

Authors:  Somaditya Mukherjee; Arun Bandyopadhyay
Journal:  Clin Proteomics       Date:  2016-11-05       Impact factor: 3.988

Review 6.  Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions.

Authors:  Maria Frantzi; Antonia Vlahou
Journal:  Bladder Cancer       Date:  2017-01-27

7.  Relevance of MIC-1 in the Era of PSA as a Serum Based Predictor of Prostate Cancer: A Critical Evaluation.

Authors:  Navneeta Bansal; Deepak Kumar; Ashish Gupta; Deepak Chandra; Satya Narain Sankhwar; Anil Mandhani
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

Review 8.  Unmasking molecular profiles of bladder cancer.

Authors:  Xuan-Mei Piao; Young Joon Byun; Wun-Jae Kim; Jayoung Kim
Journal:  Investig Clin Urol       Date:  2018-02-01

Review 9.  Proteomics and peptidomics: moving toward precision medicine in urological malignancies.

Authors:  Ashley Di Meo; Maria D Pasic; George M Yousef
Journal:  Oncotarget       Date:  2016-08-09

10.  Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.

Authors:  Simeon U Springer; Chung-Hsin Chen; Maria Del Carmen Rodriguez Pena; Lu Li; Christopher Douville; Yuxuan Wang; Joshua David Cohen; Diana Taheri; Natalie Silliman; Joy Schaefer; Janine Ptak; Lisa Dobbyn; Maria Papoli; Isaac Kinde; Bahman Afsari; Aline C Tregnago; Stephania M Bezerra; Christopher VandenBussche; Kazutoshi Fujita; Dilek Ertoy; Isabela W Cunha; Lijia Yu; Trinity J Bivalacqua; Arthur P Grollman; Luis A Diaz; Rachel Karchin; Ludmila Danilova; Chao-Yuan Huang; Chia-Tung Shun; Robert J Turesky; Byeong Hwa Yun; Thomas A Rosenquist; Yeong-Shiau Pu; Ralph H Hruban; Cristian Tomasetti; Nickolas Papadopoulos; Ken W Kinzler; Bert Vogelstein; Kathleen G Dickman; George J Netto
Journal:  Elife       Date:  2018-03-20       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.